Xerava™ (eravacycline) – New drug approval
August 27, 2018 - Tetraphase Pharmaceuticals’ announced the FDA approval of Xerava (eravacycline), for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms in patients 18 years of age and older.
Download PDF
